+Vote!
Medical News Today (Free subscription) | 06/03/2008
Nektar Therapeutics (Nasdaq: NKTR) announced new positive data from a Phase 1 clinical study for NKTR-102 (PEG-irinotecan) in advanced cancer patients whose tumors had progressed on other therapies. Significant anti-tumor activity was observed in all dose schedules of the study for NKTR-102 with partial responses observed in seven out of 44 total patients (16 percent) in the trial.
+Vote!
Medical News Today (Free subscription) | 06/03/2008
Nektar Therapeutics (Nasdaq: NKTR) announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated gene status in its Phase 2 study in advanced colorectal cancer.
+Vote!
Red Orbit (Free subscription) | 05/30/2008
SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr.
+Vote!
The San Francisco Business Times (Free subscription) | 05/22/2008
Merck & Co. executive Bharatt Chowrira is being reunited with former boss Howard Robin at Nektar Therapeutics Inc. (NKTR) (MRK) (PFE)
+Vote!
bizjournals (Free subscription) | 05/22/2008
Nektar Therapeutics Inc. on Thursday named Bharatt Chowrira chief operating officer and head of the company's PEGylation Business Unit. (NKTR)
+Vote!
PR News Wire (Free subscription) | 05/22/2008
SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (Nasdaq: ) announced today that Bharatt Chowrira, Ph.D.,
J.D. has joined the Company as Chief Operating Officer and Head of the
PEGylation Business Unit. His responsibilities include overseeing and
managing all aspects of the PEGylation Business Unit, including research
and manufacturing, as well as operations across the Company....
+Vote!
Red Orbit (Free subscription) | 05/20/2008
Bayer HealthCare and Nektar Therapeutics have reported positive preliminary Phase II data on their drug-device combination Amikacin Inhale.
+Vote!
Seeking Alpha (Free subscription) | 05/19/2008
Nektar Therapeutics (NKTR) Q1 2008 Earnings Call Complete Story »
+Vote!
Medical News Today (Free subscription) | 05/17/2008
Nektar Therapeutics (Nasdaq: NKTR) announced initial results from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors.
+Vote!
Life Science World (Free subscription) | 05/16/2008
[NEWS] Nektar’s Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ — Nektar Therapeutics (Nasdaq: NKTR) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors. The study also demonstrates...
+Vote!
Red Orbit (Free subscription) | 05/12/2008
SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide(TM), a synthetic, peptide-based erythropoiesis-stimulating agent that is under development by Takeda Global Research & Development Center, Inc.
+Vote!
Red Orbit (Free subscription) | 05/09/2008
Nektar Therapeutics has presented encouraging data from a Phase I trial, which showed that oral NKTR-118 has substantial oral bioavailability with rapid absorption and an extended half-life that is up to ten times the known half-life of unPEGylated naloxone.
+Vote!
Medical News Today (Free subscription) | 05/08/2008
New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: NKTR) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida.
+Vote!
Red Orbit (Free subscription) | 05/08/2008
SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics today announced that the U.S. Patent and Trademark Office has issued Patent No.
+Vote!
PR News Wire (Free subscription) | 05/07/2008
SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics
(Nasdaq: ) announced today the company's financial results for the
first quarter ended March 31, 2008.
Cash, cash equivalents, and short-term investments were $412.6 million
at March 31, 2008 compared to $482.4 million at December 31, 2007.
Nektar reported a net loss of $40.7 million or $0.44 per share in the
first quarter...
